Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

NCT00851552 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

9

Enrollment

OTHER

Sponsor class

Stopped Lack of sponsor support

Conditions

Lymphoma

Interventions

BIOLOGICAL: rituximab
DRUG: bortezomib
DRUG: pegylated liposomal doxorubicin hydrochloride
GENETIC: gene expression analysis
GENETIC: polymerase chain reaction
GENETIC: polymorphism analysis
GENETIC: proteomic profiling
OTHER: flow cytometry
OTHER: laboratory biomarker analysis

Sponsor

Roswell Park Cancer Institute

Collaborators

[object Object]